(Reuters) – Swiss drugmaker Novartis (NOVN.VX) beat first-quarter profit forecasts on Thursday, defying the impact of a strong dollar thanks to surprisingly strong margins. The Basel-based group confirmed its guidance for sales and operating profit growth this year. Novartis has clinched a series of deals, including a $20 billion asset swap with GlaxoSmithKline (GSK.L) finalised […]

(Reuters) – Eli Lilly and Co (LLY.N) soundly beat quarterly profit estimates on lower-than-expected spending on research and marketing, but revenue slipped as the stronger dollar hurt sales outside the United States. The U.S. drugmaker hopes to begin rebounding this year from three years of plunging sales and earnings caused by patent expirations on some […]

INDIANAPOLIS, April 23, 2015 /PRNewswire/ — Revenue declined 1 percent due to the unfavorable impact of foreign exchange rates and the continuing impact of Cymbalta and Evista patent expirations, largely offset by the inclusion of revenue from Novartis Animal Health, higher U.S. prices, and increased volume for several products. First-quarter 2015 earnings per share were […]

Abbvie chief executive Rick Gonzalez, whose team beat out several more established drug giants in the successful bid for cancer pill maker Pharmacyclics, said today new and existing products will bring “top tier growth through the rest of the decade and beyond.” Gonzalez’ bold statement, setting the stage for a larger Abbvie, came during this […]

Thousand Oaks, Calif.-based Amgen (AMGN) announced stellar first quarter revenues yesterday, deflecting a failed asthma clinical trial. The company announced a total revenue increase of 11 percent for the first quarter of 2015 compared to the same period last year, rising from $4.521 billion to $5.033 billion. Revenues were driven by sales of Enrel, Prolia, […]

– FIRST-QUARTER DOUBLE-DIGIT OPERATIONAL SALES GROWTH– FIRST-QUARTER ADJUSTED EPS FROM CONTINUING OPERATIONS OF $0.47, ABOVE PREVIOUS GUIDANCE RANGE AND REFLECTING 38 PERCENT GROWTH; GAAP EPS FROM CONTINUING OPERATIONS OF $0.35– FULL-YEAR 2015 EPS GUIDANCE RANGE FOR CONTINUING OPERATIONS REMAINS UNCHANGED– COMPLETES THE SALE OF ITS DEVELOPED MARKETS BRANDED GENERICS PHARMACEUTICALS BUSINESS ABBOTT PARK, Ill., April […]

RICHMOND, Calif., April 22, 2015 /PRNewswire/ — Sangamo BioSciences, Inc. (NASDAQ: SGMO) today reported its first quarter 2015 financial results and accomplishments. For the first quarter ended March 31, 2015, Sangamo reported a consolidated net loss of $5.3 million, or $0.08 per share, compared to a net loss of $7.6 million, or $0.12 per share, for […]

THOUSAND OAKS, Calif., April 21, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced financial results for the first quarter of 2015. Key results include:   First Quarter 2015 Product Sales Performance Product Sales Detail by Product and Geographic Region   Operating Expense and Tax Rate Analysis, on an Adjusted Basis   Cash Flow and Balance […]

DUBLIN, April 21, 2015 /PRNewswire/ — Third Quarter FY 2015 Highlights: Outlook: Perrigo Company plc (NYSE: PRGO; TASE) today announced results for its third quarter ended March 28, 2015. Chairman, President and CEO Joseph C. Papa commented, “Our results – highlighted by record fiscal third quarter net sales, adjusted net income, adjusted margins and operating cash […]